{"id":"NCT00509236","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)","officialTitle":"A Multicenter, Randomized Double-Blind Study to Evaluate the Efficacy and Safety of Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease Who Are on Dialysis and Who Have Inadequate Glycemic Control","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-10-19","primaryCompletion":"2011-03-14","completion":"2011-03-14","firstPosted":"2007-07-31","resultsPosted":"2012-05-03","lastUpdate":"2017-05-12"},"enrollment":129,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2","End-Stage Kidney Disease"],"interventions":[{"type":"DRUG","name":"Sitagliptin","otherNames":["MK-0431"]},{"type":"DRUG","name":"Glipizide","otherNames":["Glucotrol"]}],"arms":[{"label":"Sitagliptin 25 mg","type":"EXPERIMENTAL"},{"label":"Glipizide 2.5 mg - 20 mg","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the study is to compare sitagliptin and glipizide in lowering blood sugar in participants with type-2 diabetes mellitus (T2DM) and end-stage renal disease on dialysis who do not have adequate glycemic control.","primaryOutcome":{"measure":"Change From Baseline in Hemoglobin A1c After Sitagliptin Treatment","timeFrame":"Baseline / Week 54","effectByArm":[{"arm":"Sitagliptin 25 mg","deltaMin":7.89,"sd":0.74}],"pValues":[{"comp":"OG000","p":"<0.001"}]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":10},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["23352379"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":23,"n":64},"commonTop":["Blood glucose decreased","Cough","Hypoglycaemia","Hypertension","Upper respiratory tract infection"]}}